Tvardi Therapeutics, Inc. (TVRD)

Market Cap	53.14M
Revenue (ttm)	n/a
Net Income (ttm)	n/a
Shares Out	3.12M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,248
Open	16.25
Previous Close	18.25
Day's Range	15.95 - 18.99
52-Week Range	8.14 - 31.32
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About TVRD

Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis. Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency. Tvardi Therapeutics, Inc. was incorporated in 2017 and is based in Su...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: TVRD
• Website: https://tvarditherapeutics.com